We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

002195:SZSEShanghai Stonehill Technology Co., Ltd. Analysis

Data as of 2026-03-07 - not real-time

CN¥10.76

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Shanghai Stonehill Technology is trading at CNY 10.76, comfortably above its 20‑day (CNY 10.21) and 50‑day (CNY 9.48) moving averages and well above the 200‑day average (CNY 7.34), indicating a bullish price trend supported by increasing volume. The stock sits near the upper end of its technical support band at CNY 9.35 and faces resistance around CNY 11.17, while the RSI of 57 suggests neither overbought nor oversold conditions; however, the MACD histogram has turned negative and the signal line is bearish, hinting at short‑term momentum weakness. Fundamentally, the company appears severely overvalued – its trailing P/E of 359 dwarfs the industry average of 36, and a DCF‑derived fair value of only CNY 2.54 underscores the pricing disconnect. Despite a massive cash pile of CNY 7.12 bn and minimal debt, operating cash flow is negative and operating margins sit at –69%, with EBITDA also in the red and ROE barely 0.5%, reflecting weak earnings sustainability. The firm pays no dividend, so income‑focused investors have no yield buffer. Risk factors are mixed: volatility is high at 74% over the past 30 days, yet beta is low (≈0.22), indicating limited market‑wide systematic risk; regulatory scrutiny on Chinese tech firms adds a high regulatory risk, while the company’s cash strength mitigates liquidity concerns. Overall, the stock’s technical upside is outweighed by its extreme valuation and fragile profitability, suggesting caution for most investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price above short‑term moving averages supports a near‑term hold
  • Bearish MACD signal suggests limited upside momentum
  • High volatility may cause price swings in the next weeks

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Extreme trailing P/E versus industry peers
  • Negative operating cash flow and weak margins
  • DCF fair value far below current market price

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Large cash reserves provide a cushion for potential turnaround
  • Strategic shift toward AI‑driven health diagnostics could unlock growth
  • Regulatory environment and overvaluation remain significant headwinds

Key Metrics & Analysis

Financial Health

Revenue Growth3.50%
Profit Margin26.77%
P/E Ratio358.7
ROE0.48%
ROA-2.93%
Debt/Equity0.77
P/B Ratio6.1
Op. Cash FlowCN¥-332085280
Free Cash FlowCN¥454.6M
Industry P/E36.2

Technical Analysis

TrendBullish
RSI56.9
SupportCN¥9.35
ResistanceCN¥11.17
MA 20CN¥10.21
MA 50CN¥9.48
MA 200CN¥7.34
MACDBearish
VolumeIncreasing
Fear & Greed Index68.77

Valuation

Fair ValueCN¥2.54
Target PriceCN¥0.00
GradeOvervalued
TypeBlend

Risk Assessment

Beta0.22
Volatility74.27%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.